In December 2022, Zhimeng Biopharma entered into a Global Exclusive license agreement with GSK for CB06, a TLR8 agonist. Subject to successful completion of phase I, the agreement will allow GSK to develop, manufacture and commercialise CB06 for the treat
Learn moreShanghai Zhimeng Biopharma, Inc. (“Zhimeng”), an innovation-driven biopharmaceutical company focused on the development of innovative drugs for the treatment of chronic hepatitis B and central nervous system diseases, announced dosing of the first partici
Learn more
At 14:20 on November 16, 2022, GALACTIC ENERGY AEROSPACE successfully launched Ceres 1 (Yaosi) carrier rocket (mission code: YOUNG FOR YOU from Jiuquan Satellite Launch Center, successfully sending a total of 5 satellites of Gaofen 03D08, 51, 52, 53 and
Learn more
At 12:11 on August 9,2022,Galactic Energy Aerospace Company successfully launched Ceres 1 (Yao 3) · Xingguang icai carrier rocket (mission code: WHITE IS THE NEW BLACK) from Jiuquan Satellite Launch Center, successfully sending Tai102, Ping An 3 and Dongh
Learn more
Ceres I is a light commercial launch vehicle independently developed by Galactic Energy Space. It has successfully launched six commercial satellites from five satellite customers into orbit, creating a number of firsts for private rocket launches in Chin
Learn more
Recently, JIURI New Materials (688199) issued an announcement on the production of 9250 tons of series photoinitiators and intermediates in the raised investment project. According to the announcement, the main production facilities of some workshops of t
Learn moreOn April 2, 2022, focused on the liver and central nervous system diseases in the field of biological innovation, ZM BIOPHARMA announced that its independent research and development of small molecules, used in the treatment of chronic hepatitis b oral TL
Learn more
The results of the 22nd China patent award are released：CO-TRUST won the Excellence Award
Learn more
Galactic Energy completed a 1.27 billion yuan Pre-Series-B and Pre-Series-B+ Funding during July to December in 2021.
Learn more
The US Food and Drug Administration (FDA) has approved Shanghai Zhimeng Biopharma, Inc’s Investigational New Drug (IND) application for its TLR8 agonist （CB06-036） to start clinical trials for the treatment of chronic hepatitis B virus infection.
Learn more
Scan QR code
Focus on the official account of Great Filter Venture
Address: 3306 Hanjing financial center, 9968 Shennan Avenue, Nanshan District, Shenzhen
Email: info@szdawu.com
Tel: 0755-33390023
